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Aim: To investigate incidence of toxicity and related hospitalization among patients treated
at  our institute by a short course of palliative cranial radiotherapy against a longer, widely
established schedule.
Background: Shorter schedule palliative cranial radiotherapy is more  convenient for patients
and reduce waiting times. Although many studies have established safety of short sched-
ules, the need for hospitalization due to acute treatment toxicity remains under-explored.
Hospital admissions are an economic burden both for the patient and healthcare system in
a  limited resource setting. Delivery of treatment on an outpatient basis and within shorter
times is preferred by patients, caregivers and healthcare staff.
Materials and methods: This was a prospective study on 68 patients treated with palliative
whole  brain radiotherapy between November 2010 and October 2012. One group received
20  Gy in 5 fractions over 1 week and the other group, 30 Gy in 10 fractions over 2 weeks.
Treatment toxicity due to cranial radiotherapy was assessed as per RTOG acute and late
toxicity criteria. Need for hospitalization owing to acute toxicity was also noted. Signiﬁcant
differences in the study parameters between the two groups were calculated by Fisher’s
t-test.
Results: Requirement for hospital stay due to acute toxicity was not signiﬁcantly different
between the two groups. Patients in both groups experienced similar toxicity both during
and  after treatment.
Conclusions: The shorter course entailed no signiﬁcant increase in toxicity related admis-sions, suitable for limited
ﬁnancial constraints, and
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.  Background
uring the course of treatment for cancer, many  patients
evelop metastases to various organs, including the central
ervous system (CNS). CNS metastases are not an uncom-
on initial presentation in many  cancer patients and, indeed,
ccounts for the majority of CNS tumors.1,2 In India, due
o limited resources, a major proportion of the population,
specially rural, do not have adequate access to healthcare ser-
ices. Residing in remote areas with transport being difﬁcult,
reatment duration attains importance. Arranging transport
r accommodation near the treatment center becomes a con-
iderable economic burden. Under these circumstances, a
hort treatment schedule is preferred by most patients and
heir families. However, hospitals in our setting sometimes
nd it challenging to deliver short course treatment with
arger dose per fraction on an outpatient basis, owing to a per-
eption that larger dose per fraction delivered to the brain may
ause greater acute radiation toxicity that may require hospi-
alization to manage. In such an event, with an overwhelming
urden on indoor facilities, this would increase pressure on
he department workﬂow and also be detrimental to patient
afety if admission is not urgently possible. Additionally, the
xpenditure for supportive care is a ﬁnancial burden on the
atients’ family as well.
Additionally, most patients usually present with large or
ultiple lesions. These are not amenable to treatment by
ethods other than whole brain radiotherapy (WBRT). Most
ural patients who could beneﬁt from surgery or alternative
echniques, such as stereotactic radiotherapy, do not have
ccess to those services. In the absence of alternative man-
gement, it is sometimes compelling to treat these patients
ith WBRT,  too.
The safety of short schedule palliative WBRT  has been
stablished by clinical studies.3,4 A review of literature reveals
vidence suggesting similar progression and survival between
hort schedules of palliative WBRT,  as opposed to the widely
stablished 30 Gy in 10 fractions over 2weeks schedule.5,6
elivery of palliative radiotherapy for brain metastases in as
ew as 2 fractions has also been documented in certain situa-
ions, with comparable results.7
Cranial radiotherapy may lead to treatment-related toxi-
ities that may be stressful to the patient and their caregivers.
he toxicity-related hospital admission may put economic
ressures on the healthcare system, on the patient and their
amilies. A comprehensive search of Pubmed does not reveal
tudies that compare acute toxicity due to short fractionation
chedules with that of prolonged schedules.
.  Aim
e  compared the toxicity and the related need for hospitaliza-
ion among patients treated with a 20 Gy in 5 fractions over 1
eek schedule with 30 Gy in 10 fractions over 2 weeks. Primary
ndpoints were the incidence of acute toxicity and toxicity-
elated need for hospitalization. The secondary objective was
he incidence of late toxicity.therapy 1 9 ( 2 0 1 4 ) 428–432 429
3.  Materials  and  methods
3.1.  Patients
The study included 68 patients with brain metastases treated
with palliative cranial radiotherapy at our institute between
November 2010 and October 2012. Thirty-eight had received
30 Gy in 10 fractions over 2 weeks, whereas 30 patients had
been treated with 20 Gy in 5 fractions over 1 week. Majority
of the patients had breast or lung cancer. The patients who
had received 30 Gy in 10 fractions over 2 weeks (n = 38) had
similar characteristics as the group that received short course
treatment (n = 30) (Table 1).
Five patients had brain metastases at initial diagnosis of
cancer. Nineteen patients (63.33%) from the short course group
and 30 patients (78.94%) from the group that received longer
course of radiotherapy had only brain metastases at the time
of cranial radiotherapy. Seven patients (23.33%) from the short
course group and 5 patients (13.15%) from the other group
had metastases to a single site apart from the brain at the
time of receiving palliative cranial radiotherapy. Four patients
(13.33%) from the short course group and 3 patients (7.89%)
from the longer course group had metastases to more  than
one non-CNS site at the time of receiving cranial radiotherapy
and these patients had a Karnofsky Performance Score of <40
at the time of cranial radiotherapy (Table 2).
3.2.  Treatment
3.2.1.  Radiation  therapy
All patients received radiation to the whole brain once daily,
ﬁve days per week.
Patients were treated in a supine position. Parallel opposed
lateral ﬁelds were used with the gantry at 90◦ and 270◦. The
ﬁeld borders were 2 cm beyond the skull in the superior, ante-
rior, and posterior margin, and the lower border of C2 vertebra
in the inferior margin. All patients were treated by telecobalt.
As per institutional protocol, all patients received dexa-
methasone 2 mg orally twice daily during the period of cranial
radiotherapy.
3.2.2.  Follow-up
Patients were assessed daily during radiotherapy by the physi-
cian for any symptoms of treatment-related acute toxicity. On
completion of WBRT,  they were seen after 1 week at the radi-
ation oncology department to be assessed for any problems
related to daily activities, self care and any worsening of symp-
toms since the completion of treatment. Also, it is necessary
to address the caregivers concerns in view of the absence of
social support services in our setting. After that, patients were
followed up at medical or radiation oncology at 1 month, fol-
lowed by 3 monthly for as long as the patient remained alive or
attended hospital. Toxicity was graded using the RTOG acute
and late toxicity criteria.3.3.  Statistical  analysis
Data of patients who received 20 Gy in 5 fractions over 1 week
(n = 30) was compared to that of the group treated by 30 Gy
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Table 1 – Patient characteristics.
Patient demographic
data in both groups
Patients who received
20 Gy/5#/1 week
Patients who  received
30 Gy/10#/2 weeks
n = 30 n = 38
Gender
Male 21 27
Female 19 11
Age Median: 48 year (range 38–55 year) Median: 52 year (range 40–73 year)
Primary site
Breast 10 14
Lung 8 10
Prostate 2 3
Bladder 1 0
Rectum 1 0
Anal canal 1 0
PNET 2 2
Renal cell carcinoma 2 4
Vulva 1 0
Unknown primary 2 5
Performance status at diagnosis
KPS >70 13 18
KPS 50–70 10 15
KPS <50 7  5
RPA class
Class 1 11 13
Class 2 2 5
Class 3 17 20
Number of brain metastases
Single 11 21
Multiple 19 
in 10 fractions over 2 weeks (n = 38). Acute toxicity needs for
hospital stay due to treatment toxicity, as well as late toxicity
were noted. Patients who died during the course of follow up
were excluded for late toxicity but included for acute toxicity
analysis.
Fisher’s t-test was used to assess the endpoints.
Statistical analysis was done using the GraphPad Quick-
Calcs Web site: http://www.graphpad.com/quickcalcs/
contingency1 (accessed November 2012).
4.  ResultsMedian age of patients in the short course group was 48
years (range 38–55 years) and 52 years (range 40–68 years)
in those receiving long course radiotherapy. 75% of patients
had initially presented with locally advanced tumors; 11 of
Table 2 – Distribution of metastases at time of cranial radiother
Metastases at initiation
of cranial radiotherapy
CNS metastases only Solitary 
Multiple 
Simultaneous
non-CNS metastases
present at time of
cranial radiotherapy
Patients with single metastasis
(non-CNS) at start of cranial
radiotherapy
Patients with more than 2 metastatic
sites (non-CNS)17
30 patients (36.66%) from the short course group and 8 of
38 patients (21.05%) from the longer course group had non-
CNS systemic metastases at the time of diagnosis of brain
metastases. 36.66% patients from the short course group and
36.84% patients from the longer course group had multiple
brain metastases. Patients having solitary brain metastases
had either large lesions or were not amenable for surgery due
to medical reasons. These patients comprised 26.66% of the
shorter schedule group and 42.10% of the group that received
a longer course of radiotherapy.
Overall, patients had a median follow-up of 6 months
(range 2–16 months). Median follow up for the short course
group was 7 months and that for the longer course group
was 5 months. Thirteen patients (43.33%) who received the
short course and 17 patients (44.73%) who received long course
radiotherapy continued follow up beyond 6 months. 93.33%
of these patients were of RPA class 1 and 2. One  patient
apy.
Patients receiving 20 Gy/5
fractions/1 week (n = 30)
Patients receiving 30 Gy/10
fractions/2 weeks (n = 38)
8 16
11 14
7  5
4  3
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Fig. 1 – Incidence of acute toxicity.
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dho  had received 20 Gy/5 fractions/1 week, died one month
fter the completion of treatment due to widespread visceral
etastases, however his pre-treatment performance status
as KPS 20. Two patients from the longer course died within
 weeks of the completion of treatment, one at 10 days
ue to thromboembolism, and the other patient at 3 weeks
ue to widespread metastatic disease. Pre-treatment perfor-
ance status of this patient was KPS 30. These patients were
xcluded from late toxicity analysis but included for acute
oxicity analysis.
.1.  Acute  toxicity  (Fig.  1)
ncidence of acute RTOG toxicity was not signiﬁcantly differ-
nt between the two groups (two-tailed P value = 0.5574). No
reatment interruption was required due to toxicity.
.2.  Need  for  hospital  admission  during  treatment
uring the course of treatment, 2 patients from the short
ourse arm and 4 patients from the 30 Gy/10 fractions arm
eeded hospital stay due to sudden onset of limb weakness in
ne patient, repeated seizure episodes in 3 patients and difﬁ-
ulty in feeding orally in 2 patients. None of these patients had
hese problems prior to the start of cranial radiotherapy. Hos-
ital stay due to acute CNS toxicity was also not signiﬁcantly
ifferent between the two groups (two tailed P = 0.6871).
Fig. 2 – Incidence of late toxicity.therapy 1 9 ( 2 0 1 4 ) 428–432 431
4.3.  Late  toxicity  (Fig.  2)
Two patients receiving the short course schedule developed
RTOG grade 1 late toxicity. Among these patients, one had
developed grade 2 acute toxicity during treatment. No grade
2, 3 or 4 late toxicities were noted. The two-tailed P value was
0.4472.
5.  Conclusions
The most widely used fractionation schedule for palliative
cranial radiotherapy is usually 30 Gy/10 fractions/2 weeks. Var-
ious studies on altered fractionation in palliative radiotherapy
for brain metastases have established the safety of alternative
schedules. Some studies have used doses lower than 300 cGy
per fraction while other employed higher fraction sizes with
shorter overall treatment time.
It has been demonstrated that lower doses per fraction
up to a higher total dose have not necessarily translated to
improved survival outcomes or lower treatment toxicity. In the
study by Murray et al., no advantage in terms of grade 3 and
4 toxicity were noted in the patient group treated by accel-
erated hyperfractionation at 1.6 Gy per fraction twice daily
up to a total dose of 54.4 Gy.5 Survival at one year was 19%
among patients who received the hyperfractionated sched-
ule as opposed to 16% in the hypofractionated treatment
group who received 30 Gy/10 fractions/2 weeks. As described
by Borgelt et al., various shorter fractionation schedules that
were analyzed in terms of response and survival showed com-
parable results, favoring no particular schedule.6
Development of acute radiation toxicity is stressful for
patients and their families. It may be particularly difﬁcult for
caregivers who have to deal with this additional crisis in an
already stressful scenario.8 The occurrence of acute radiation
toxicity may also necessitate hospital admission. Unfortu-
nately, hospital admission has a signiﬁcant impact on the
healthcare system in this setting of limited resources. This
makes decision making especially challenging for physicians
and healthcare staff.
Under these circumstances, it was compelling to study
the incidence of radiation toxicity among these patients who
require a shorter treatment time causing least inconvenience,
and comparable toxicity to a more  widely used albeit longer
schedule.
Studies in literature comparing results of shorter fraction-
ation schedules for palliative cranial radiotherapy found no
signiﬁcant increase in radiotherapy toxicity among patients
treated by shorter schedules. In the study by Priestman et al.,3
radiation related side effects, other than alopecia, were seen in
12% of patients receiving two fractions and 8% of those given
10 fractions.
In our study, acute toxicity between the two  radiation
schedules was comparable. The shorter schedule of treatment
did not seem to increase the need for hospital stay, which was
an advantage for the patients. Also, the secondary endpoint,
late toxicity during the follow up did not signiﬁcantly differ
between the groups.
Studies in literature point out a worsening of the qual-
ity of life in patients who receive radiotherapy for brain
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9. Fernandez G, Pocinho R, Travancinha C, et al. Quality of life
and radiotherapy in brain metastasis patients. Rep Pract Oncol
Radiother 2012;17(5):281–7.432  reports of practical oncology an
metastases.9 Whether quality of life depends on fractionation
schedules, and whether different fractionation produces vary-
ing effects on the quality of life and neurocognitive decline, is
still underexplored.
Owing to the short duration of follow up and the limited
number of patients that could be studied, generalization of
these results is limited, further studies are needed in this
regard. Also, survival data for our patient group is not avail-
able for the entire cohort owing to considerable drop out from
follow up, which is not uncommon among patients in our sce-
nario. Communicating with patients who  are lost to follow
up is not feasible in most cases because of remote areas of
residence and lack of infrastructure. As a consequence, these
results are not being published.
Despite these limitations, our study shows that a shorter
duration of treatment did not affect the hospital admission
rate in our patients. Palliation and treatment toxicity were
comparable. Patients found the shorter duration of therapy
more acceptable, the burden on hospitalization did not signif-
icantly differ, both of which are essential in this setting.
Delivering larger doses per fraction on an outpatient basis
was found to be safe and feasible with similar outcomes in
our patients. The shorter course of palliative cranial radio-
therapy was not associated with more  toxicity and did not
signiﬁcantly alter hospitalization rates during treatment. It
was convenient and more  acceptable for patients as well as
their caregivers; additionally, it helped reduce patient waiting
times in the radiation oncology department.
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